An understanding of the mechanism, and the second messengers that mediate TRPV1 sensitization, following PAR2 activation might suggest a method for pharmacologic antagonism and treatment for oral cancer pain. The gene discussed is F2RL1; the disease is lip and oral cavity carcinoma.